Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is an American multinational medical technology company headquartered in Franklin Lakes, New Jersey. Founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson, it later moved its headquarters to New Jersey. BD is a publicly traded company on the NYSE under the ticker symbol BDX and is a component of the S&P 500. As of 2025, BD reported approximately 72,000 employees and an estimated revenue of US$21.8 billion.

BD develops, manufactures, and sells a wide range of medical devices, instrument systems, reagents, and diagnostic products globally. The company operates through three primary segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on medication management and delivery solutions, including syringes, needles, and infusion pumps. BD Life Sciences provides products for specimen collection, diagnostics, and research, such as flow cytometry instruments and molecular diagnostics. BD Interventional offers devices for minimally invasive surgical and interventional procedures, including peripheral intervention and urology.

Becton, Dickinson and Company's patent litigation posture appears to be that of an operating company defending against assertion suits. The company has been involved in 1 tracked case as a defendant and 0 as a plaintiff, suggesting it is primarily a target rather than an enforcer of patents in the current dataset. The single tracked case, Lone Star SCM Systems, LP v. Becton, Dickinson and Company, was filed in the Texas Western District Court in 2021.

The tracked case, Lone Star SCM Systems, LP v. Becton, Dickinson and Company, highlights BD's involvement in defensive patent litigation. While the specific technology asserted in this case is not detailed in the provided data, BD's extensive product portfolio across medical technology suggests potential litigation could relate to various aspects of medical devices, diagnostics, or laboratory equipment.